Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan

被引：0
|
作者：
Palshof, Jesper Andreas
Christensen, Troels Dreier
Poulsen, Tim Svendstrup
Jensen, Benny Vittrup
Linnemann, Dorte
Schou, Jakob Vasehus
Pfeiffer, Per
Yilmaz, Mette K. N.
Christensen, Ib Jarle
Hogdall, Estrid V.
Nielsen, Dorte
机构：
[1] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark
[2] Herlev Univ Hosp, Dept Oncol, Herlev, Denmark
[3] Herlev Univ Hosp, Dept Pathol, Herlev, Denmark
[4] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Copenhagen, Denmark
[5] Herlev Univ Hosp, Herlev, Denmark
[6] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[7] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
[8] Herlev Hosp, Univ Copenhagen, Dept Pathol, Herlev, Denmark
[9] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15115
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
    Fornaro, Lorenzo
    Baldi, Giacomo Giulio
    Masi, Gianluca
    Allegrini, Giacomo
    Loupakis, Fotios
    Vasile, Enrico
    Cupini, Samanta
    Stasi, Irene
    Salvatore, Lisa
    Cremolini, Chiara
    Vincenzi, Bruno
    Santini, Daniele
    Tonini, Giuseppe
    Graziano, Francesco
    Ruzzo, Annamaria
    Canestrari, Emanuele
    Magnani, Mauro
    Falcone, Alfredo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (03) : 243 - 251
  • [2] CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-RESISTANT ELDERLY METASTATIC COLORECTAL CANCER PATIENTS: CLINICAL OUTCOME ACCORDING TO KRAS AND BRAF MUTATIONAL STATUS
    Baldi, G.
    Fornaro, L.
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Allegrini, G.
    Marcucci, L.
    Stasi, I
    Santini, D.
    Tonini, G.
    Graziano, F.
    Ruzzo, A.
    Magnani, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 77 - 77
  • [3] Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan
    Gonzalez-Baron, M.
    Blanco, M.
    Feliu, J.
    Gomez, C.
    Casado, E.
    Castro, J.
    Belda-Iniesta, C.
    Garrido, M.
    Aguayo, C.
    Campos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Cetuximab and irinotecan in patients with EGFR plus colorectal cancer refactory to oxaliplatin and irinotecan: A single institution experience
    Herrero, A
    Alonso, V
    Lao, J
    de Lobera, AR
    Pazo, R
    Martinez-Trufero, J
    Puertolas, T
    Calderero, V
    Artal, A
    Anton, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 302S - 302S
  • [5] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    Sobrero, Alberto F.
    Maurel, Joan
    Fehrenbacher, Louis
    Scheithauer, Werner
    Abubakr, Yousif A.
    Lutz, Manfred P.
    Vega-Villegas, M. Eugenia
    Eng, Cathy
    Steinhauer, Ernst U.
    Prausova, Jana
    Lenz, Heinz-Josef
    Borg, Christophe
    Middleton, Gary
    Kroening, Hendrik
    Luppi, Gabriele
    Kisker, Oliver
    Zubel, Angela
    Langer, Christiane
    Kopit, Justin
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2311 - 2319
  • [6] Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan
    Vincenzi, B
    Santini, D
    Tonini, G
    ANNALS OF ONCOLOGY, 2006, 17 (03)
  • [7] EFFECT OF ENZASTAURIN IN PATIENTS WITH COLORECTAL CANCER TREATED WITH IRINOTECAN PLUS CETUXIMAB
    Iqbal, S.
    Miller, C.
    Figueroa, J.
    Hossain, A.
    Nicol, S.
    Mulcahy, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 66 - 66
  • [8] Cetuximab plus irinotecan in refractory colorectal cancer patients
    Delgao, Marian Gil
    Spano, Jean-Philippe
    Khayat, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 407 - 413
  • [9] Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
    Vincenzi, Bruno
    Santini, Daniele
    Russo, Antonio
    Gavasci, Michele
    Battistoni, Fabrizio
    Dicuonzo, Giordano
    Rocci, Laura
    Rosaria, Valerio Maria
    Gebbia, Nicola
    Tonini, Giuseppe
    PHARMACOGENOMICS, 2007, 8 (04) : 319 - 327
  • [10] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
12345